 |
|
Trends in Adherence to a Revised Risk Management Program Designed to Decrease or Eliminate Isotretinoin-Exposed Pregnancies
Evaluation of the Accutane SMART Program
Allen Brinker, MD, MS;
Cynthia Kornegay, PhD;
Parivash Nourjah, PhD
Arch Dermatol. 2005;141:563-569.
Objective To review adherence to selected procedures outlined in the System to Manage Accutane-Related Teratogenicity (SMART) program during the first year of implementation vs the procedures in effect in the year prior to initiation of the SMART program.
Design Observational.
Setting A novel pharmacy compliance survey and an ongoing, voluntary survey.
Patients Female recipients of isotretinoin.
Intervention In April 2002, Hoffmann-La Roche Inc, Nutley, NJ, manufacturer of Accutane brand isotretinoin and at that time the sole source of isotretinoin, revised earlier guidelines and instituted the SMART risk management program, which included the use of qualification stickers to affix to all prescriptions for Accutane to indicate, among other things, a negative pregnancy test just before the prescription was written. The goal of the SMART program was to decrease or eliminate isotretinoin-exposed pregnancies.
Main Outcome Measures Use and completion of prescription qualification stickers; changes in pretherapy pregnancy testing and birth control use.
Results The results of the pharmacy compliance survey indicated high (>90%) use of prescription qualification stickers. Results of the patient survey suggested that 9% of prescription qualification stickers within the observed user cohort were issued without a pregnancy test. Furthermore, the pregnancy rate for patients participating in the survey was similar to that reported for cohorts recruited before the SMART program.
Conclusions The usefulness of the results derived from 2 surveys designed to evaluate the SMART program is limited by the lack of reliability and validity of the survey instruments and by questionable generalizability to all female recipients of isotretinoin. The presence of a qualification sticker may not have an impact on pregnancy testing or compliance with effective birth control behavior as outlined in the SMART program.
Author Affiliations: Food and Drug Administration, Center for Drug Evaluation and Research, Office of Drug Safety, Rockville, Md.
RELATED ARTICLES
Isotretinoin Therapy and Mood Changes in Adolescents With Moderate to Severe Acne: A Cohort Study
Christina Y. Chia, Whitney Lane, John Chibnall, Angel Allen, and Elaine Siegfried
Arch Dermatol. 2005;141(5):557-560.
ABSTRACT
| FULL TEXT
Relationship Between Headache and Depression in Users of Isotretinoin
Diane K. Wysowski and Lynette Swartz
Arch Dermatol. 2005;141(5):640-641.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Review of eight restricted-access programs and potential implications for pharmacy
Evans and Evans
Am J Health Syst Pharm 2007;64:1302-1310.
FULL TEXT
|
